Mark Voskoboynik

Publication Activity (10 Years)

Years Active: 2014-2020
Publications (10 Years): 3

Top Topics

Prognostic Factors

Ejection Fraction

African American

Basal Cell Carcinoma

Top Venues

Melanoma management

BJU international

Drug design, development and therapy

Biochemistry research international

This page only lists publications with an associated author ORCID identifier.

Publications

Jason D Lickliter, Hui K Gan, Mark Voskoboynik, Surein Arulananda, Bo Gao, Adnan Nagrial, Peter Grimison, Michelle Harrison, Jianjun Zou, Lianshan Zhang, Stacey Luo, Michael Lahn, Howard Kallender, Andrea Mannucci, Catello Somma, Katherine Woods, Andreas Behren, Pablo Fernandez-Penas, Michael Millward, Tarek Meniawy
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug design, development and therapy 14 (2020)
Evangeline Samuel, Maggie Moore, Mark Voskoboynik, Mark Shackleton, Andrew Haydon
An update on adjuvant systemic therapies in melanoma. Melanoma management 6 (3) (2019)
Mark Voskoboynik, Victoria Mar, Sonia Mailer, Andrew Colebatch, Anne Fennessy, Aleksandra Logan, Chelsee Hewitt, Jonathon Cebon, John Kelly, Grant McArthur
Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma. Pigment cell & melanoma research 29 (2) (2016)
Mark Voskoboynik, Sarah Rudman, Hendrik-Tobias Arkenau, Simon Hughes, Simon Chowdhury
Immunotherapy for bladder cancer: rediscovering an old friend. BJU international 117 (5) (2015)
Mark Voskoboynik, Hendrik-Tobias Arkenau
Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochemistry research international 2014 (2014)